Professor Jim Al-Khalili

This BBC podcast is supported by ads outside the UK.

Hei! Asempic, Wegovi, Manjaro. Juuri muutama vuosi sitten meitä ei ole koskaan kuullut näistä nimeistä. Nyt ne ovat kaikkialla. Heidät ovat ilmaiset vahvistusrugit, jotka auttavat ihmisiä vahvistamaan poundeja replikaatioon GLP-1-hormonin, joka kertoo, että olet syönyt tarpeeksi ja vahvistaa pankreasi insulinaan.

One of the leading researchers behind this breakthrough is Jens Juul Holst, professor of medical physiology and biomedical sciences at the University of Copenhagen, whose work in the 1980s helped discover and decode GLP-1. Over the decades since then, Jens has laid the groundwork for today's wonder drugs that are changing the lives of millions worldwide by treating obesity and diabetes.

Tämä on saanut Jensin suurta suurta profiilia, kuten Breakthrough Prize ja Tang Prize. Ja hän oli nimeltään Time-magazineissa 100 suurimpia ihmisiä terveydenhuollossa vuonna 2024. Mutta suuri voima on tullut suuri, iso kysymys. GLP-1-drugin asemaa ei vain reshapaa terveydenhuoltoa, vaan myös vahvistaa keskustelua siitä, miten ne pitäisi käyttää ja mitä ne tarkoittavat pitkäaikaisen terveydenhuollon ja terveydenhuollon.

So hopefully we'll get some of those questions answered today. Jens Juhlholz, welcome to the Life Scientific. Thank you very much and thank you very much for asking me to do this. Certainly a lot of people will have heard about weight loss jabs in recent years. How exactly do they work? The interesting new thing about them is that they inhibit appetite.

So this is my interest here and we know that there is a large number of complications to obesity. And that's what you can do something about with these new medications. And I think that's fantastic. Well, we're certainly going to talk about a lot of these hugely positive results, but concerns have been raised, including by you. You said a couple of years ago that the success of GLP-1 drugs has brought new scientific, clinical and ethical questions that the medical community needs to navigate with care.

Well, after those difficult early years, things, as you say, did improve. You were a good student academically, but initially you wanted to focus on something other than science. You were very keen on music. Yeah, yeah. For a while in school I thought that maybe I should end up doing something with music. Today I'm quite happy that I didn't. I think that that would have been a tough life. Fun, but tough.

As you say, you went to study medicine at the University of Copenhagen and you really threw yourself into student life.

Mutta se oli hieno aamu, ja luulen, että se käsitteli mielestäni terveyden ja yhteiskunnan ja muuta. Luulen, että se oli erittäin hyödyllistä. Joulua sitten aloitit työskennellä Bispebjörg Hospitalissa, joka sitten tuli yhdessä yliopistoon Kopenhagenin yliopistoon. Se tarkoittaa sitä, että olit vahvistunut tutkimukseen klinikkojen kanssa.

And they were of course designated glucagon-like peptides 1 and glucagon-like peptides 2. Which is the GLP, yes. And that's the GLP-1 and GLP-2, yeah. Right. So that opened the field, I must say. And it's a lot of technical detail there, but I think it's important because if you come to talking about these weight loss drugs, they all rely on this glucagon-like peptide GLP-1. Yes.

In 1993 your team provided the first clinical evidence that GLP-1 could help patients with diabetes. You told us about GLP-1 itself, but how exactly was that translated into a treatment for diabetes? How did it work?

Tietysti, kuten mainitsimme, kaikki tämä oli lopputuloksen lopputulokset ja ei vain yksi Eureka-momentti. Mutta diabetes-ympäristönä tämä lopputuloksi oli iso. Muistatko, miten tuntit siitä aiemmin? Tämä osoittaminen täysin normaalista glukoosileveä tarkoittaa, että emme vain itsemme, vaan myös

Kyllä, ja se tuntui vähentämään kardiovaskulaatioiden vaikutuksia melko suuremmin. Se oli mahtava yllätys. Se on ilmeistä, toivottavasti. Haluan tulla takaisin siihen hieman myöhemmin, mutta jälkeenpäin, Jens, GLP-1-terapiat, joita te ja muut kehittivät, käsittelevät niihin medikaatioihin, joita näemme tänään.

So that's really fantastic, I think. That's incredible. So various positive and unexpected impacts. But as with almost any new medication, there are of course also concerns. And one that's been covered quite recently in the media is possible swift weight regain after stopping treatment. What's your reaction to that? So first of all, it was predicted.

where you have reached a nice plateau of new body weight. Well, it's the good habits that I think is the important thing here, isn't it? Using these drugs as part of a properly prescribed weight loss plan with your GP support around, as you say, diet and exercise. But that actually speaks to another concern, which is about people getting these drugs from unofficial sources without any medical advice.

Another problem right now is cost. There was a BBC investigation last year reporting that out of an estimated one and a half million people using these drugs in the UK, nine in ten are believed to pay privately.

Ja vaikka rauhoitumiset ovat erilaisia dosioiden kanssa, olet yleensä katsomassa monia kymmenellä kuukautta kuukautta, mikä on erityisesti vaikeaa, kun ajattelet, että diabetesi ja opetuksen ratkaisut ovat kuitenkin suurempia asiakkaiden yliopistossa. Mikä voisi auttaa laajentamaan kosteuksia? Tämä kysymys on tietenkin erittäin tärkeä.